S&P 500   3,629.65 (-0.16%)
DOW   29,872.47 (-0.58%)
S&P 500   3,629.65 (-0.16%)
DOW   29,872.47 (-0.58%)
S&P 500   3,629.65 (-0.16%)
DOW   29,872.47 (-0.58%)
S&P 500   3,629.65 (-0.16%)
DOW   29,872.47 (-0.58%)
Log in
NASDAQ:VNDA

Vanda Pharmaceuticals Competitors

$12.11
-0.23 (-1.86 %)
(As of 11/25/2020 12:00 AM ET)
Add
Compare
Today's Range
$12.05
Now: $12.11
$12.77
50-Day Range
$10.02
MA: $11.44
$13.25
52-Week Range
$7.12
Now: $12.11
$17.85
Volume410,054 shs
Average Volume651,316 shs
Market Capitalization$662.32 million
P/E Ratio5.79
Dividend YieldN/A
Beta0.48

Competitors

Vanda Pharmaceuticals (NASDAQ:VNDA) Vs. AMGN, GILD, VRTX, REGN, BIIB, and SGEN

Should you be buying VNDA stock or one of its competitors? Companies in the sub-industry of "biotechnology" are considered alternatives and competitors to Vanda Pharmaceuticals, including Amgen (AMGN), Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), and Seagen (SGEN).

Amgen (NASDAQ:AMGN) and Vanda Pharmaceuticals (NASDAQ:VNDA) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, earnings, institutional ownership, dividends, valuation, analyst recommendations and risk.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Amgen and Vanda Pharmaceuticals, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Amgen1121502.50
Vanda Pharmaceuticals12402.43

Amgen presently has a consensus target price of $254.08, indicating a potential upside of 15.33%. Vanda Pharmaceuticals has a consensus target price of $15.3333, indicating a potential upside of 26.62%. Given Vanda Pharmaceuticals' higher probable upside, analysts plainly believe Vanda Pharmaceuticals is more favorable than Amgen.

Earnings and Valuation

This table compares Amgen and Vanda Pharmaceuticals' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Amgen$23.36 billion5.49$7.84 billion$14.8214.87
Vanda Pharmaceuticals$227.19 million2.92$115.55 million$2.115.74

Amgen has higher revenue and earnings than Vanda Pharmaceuticals. Vanda Pharmaceuticals is trading at a lower price-to-earnings ratio than Amgen, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Amgen has a beta of 0.81, meaning that its share price is 19% less volatile than the S&P 500. Comparatively, Vanda Pharmaceuticals has a beta of 0.48, meaning that its share price is 52% less volatile than the S&P 500.

Insider and Institutional Ownership

71.7% of Amgen shares are owned by institutional investors. 0.4% of Amgen shares are owned by insiders. Comparatively, 5.9% of Vanda Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares Amgen and Vanda Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Amgen29.42%95.55%15.52%
Vanda Pharmaceuticals47.31%27.43%23.31%

Summary

Amgen beats Vanda Pharmaceuticals on 10 of the 14 factors compared between the two stocks.

Vanda Pharmaceuticals (NASDAQ:VNDA) and Gilead Sciences (NASDAQ:GILD) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, earnings, profitability, dividends, risk, analyst recommendations and institutional ownership.

Risk and Volatility

Vanda Pharmaceuticals has a beta of 0.48, suggesting that its stock price is 52% less volatile than the S&P 500. Comparatively, Gilead Sciences has a beta of 0.53, suggesting that its stock price is 47% less volatile than the S&P 500.

Institutional & Insider Ownership

77.9% of Gilead Sciences shares are owned by institutional investors. 5.9% of Vanda Pharmaceuticals shares are owned by insiders. Comparatively, 0.1% of Gilead Sciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Valuation and Earnings

This table compares Vanda Pharmaceuticals and Gilead Sciences' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Vanda Pharmaceuticals$227.19 million2.92$115.55 million$2.115.74
Gilead Sciences$22.45 billion3.32$5.39 billion$6.149.69

Gilead Sciences has higher revenue and earnings than Vanda Pharmaceuticals. Vanda Pharmaceuticals is trading at a lower price-to-earnings ratio than Gilead Sciences, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current recommendations and price targets for Vanda Pharmaceuticals and Gilead Sciences, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Vanda Pharmaceuticals12402.43
Gilead Sciences2151002.30

Vanda Pharmaceuticals currently has a consensus target price of $15.3333, suggesting a potential upside of 26.62%. Gilead Sciences has a consensus target price of $76.1538, suggesting a potential upside of 27.99%. Given Gilead Sciences' higher possible upside, analysts plainly believe Gilead Sciences is more favorable than Vanda Pharmaceuticals.

Profitability

This table compares Vanda Pharmaceuticals and Gilead Sciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Vanda Pharmaceuticals47.31%27.43%23.31%
Gilead Sciences5.48%37.77%12.76%

Summary

Gilead Sciences beats Vanda Pharmaceuticals on 10 of the 14 factors compared between the two stocks.

Vanda Pharmaceuticals (NASDAQ:VNDA) and Vertex Pharmaceuticals (NASDAQ:VRTX) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, risk, dividends, profitability, earnings, institutional ownership and valuation.

Risk & Volatility

Vanda Pharmaceuticals has a beta of 0.48, indicating that its share price is 52% less volatile than the S&P 500. Comparatively, Vertex Pharmaceuticals has a beta of 0.79, indicating that its share price is 21% less volatile than the S&P 500.

Profitability

This table compares Vanda Pharmaceuticals and Vertex Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Vanda Pharmaceuticals47.31%27.43%23.31%
Vertex Pharmaceuticals38.51%28.55%20.68%

Institutional & Insider Ownership

92.2% of Vertex Pharmaceuticals shares are held by institutional investors. 5.9% of Vanda Pharmaceuticals shares are held by company insiders. Comparatively, 0.7% of Vertex Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Analyst Recommendations

This is a summary of recent ratings for Vanda Pharmaceuticals and Vertex Pharmaceuticals, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Vanda Pharmaceuticals12402.43
Vertex Pharmaceuticals082212.77

Vanda Pharmaceuticals currently has a consensus target price of $15.3333, suggesting a potential upside of 26.62%. Vertex Pharmaceuticals has a consensus target price of $290.5862, suggesting a potential upside of 33.24%. Given Vertex Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Vertex Pharmaceuticals is more favorable than Vanda Pharmaceuticals.

Valuation and Earnings

This table compares Vanda Pharmaceuticals and Vertex Pharmaceuticals' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Vanda Pharmaceuticals$227.19 million2.92$115.55 million$2.115.74
Vertex Pharmaceuticals$4.16 billion13.62$1.18 billion$4.2950.84

Vertex Pharmaceuticals has higher revenue and earnings than Vanda Pharmaceuticals. Vanda Pharmaceuticals is trading at a lower price-to-earnings ratio than Vertex Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Summary

Vertex Pharmaceuticals beats Vanda Pharmaceuticals on 12 of the 15 factors compared between the two stocks.

Vanda Pharmaceuticals (NASDAQ:VNDA) and Regeneron Pharmaceuticals (NASDAQ:REGN) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, earnings, institutional ownership, dividends, profitability, risk and valuation.

Volatility & Risk

Vanda Pharmaceuticals has a beta of 0.48, suggesting that its stock price is 52% less volatile than the S&P 500. Comparatively, Regeneron Pharmaceuticals has a beta of 0.51, suggesting that its stock price is 49% less volatile than the S&P 500.

Analyst Ratings

This is a summary of current recommendations for Vanda Pharmaceuticals and Regeneron Pharmaceuticals, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Vanda Pharmaceuticals12402.43
Regeneron Pharmaceuticals0101312.63

Vanda Pharmaceuticals presently has a consensus target price of $15.3333, indicating a potential upside of 26.62%. Regeneron Pharmaceuticals has a consensus target price of $628.52, indicating a potential upside of 23.65%. Given Vanda Pharmaceuticals' higher possible upside, research analysts clearly believe Vanda Pharmaceuticals is more favorable than Regeneron Pharmaceuticals.

Profitability

This table compares Vanda Pharmaceuticals and Regeneron Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Vanda Pharmaceuticals47.31%27.43%23.31%
Regeneron Pharmaceuticals37.30%26.71%19.39%

Institutional and Insider Ownership

85.9% of Regeneron Pharmaceuticals shares are held by institutional investors. 5.9% of Vanda Pharmaceuticals shares are held by insiders. Comparatively, 11.8% of Regeneron Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Earnings and Valuation

This table compares Vanda Pharmaceuticals and Regeneron Pharmaceuticals' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Vanda Pharmaceuticals$227.19 million2.92$115.55 million$2.115.74
Regeneron Pharmaceuticals$7.86 billion6.90$2.12 billion$21.4723.68

Regeneron Pharmaceuticals has higher revenue and earnings than Vanda Pharmaceuticals. Vanda Pharmaceuticals is trading at a lower price-to-earnings ratio than Regeneron Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Summary

Regeneron Pharmaceuticals beats Vanda Pharmaceuticals on 11 of the 15 factors compared between the two stocks.

Vanda Pharmaceuticals (NASDAQ:VNDA) and Biogen (NASDAQ:BIIB) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, risk, valuation, earnings and dividends.

Earnings & Valuation

This table compares Vanda Pharmaceuticals and Biogen's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Vanda Pharmaceuticals$227.19 million2.92$115.55 million$2.115.74
Biogen$14.38 billion2.59$5.89 billion$33.577.20

Biogen has higher revenue and earnings than Vanda Pharmaceuticals. Vanda Pharmaceuticals is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Vanda Pharmaceuticals has a beta of 0.48, meaning that its stock price is 52% less volatile than the S&P 500. Comparatively, Biogen has a beta of 0.61, meaning that its stock price is 39% less volatile than the S&P 500.

Profitability

This table compares Vanda Pharmaceuticals and Biogen's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Vanda Pharmaceuticals47.31%27.43%23.31%
Biogen35.63%51.00%23.54%

Analyst Recommendations

This is a summary of current ratings and price targets for Vanda Pharmaceuticals and Biogen, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Vanda Pharmaceuticals12402.43
Biogen5151302.24

Vanda Pharmaceuticals currently has a consensus price target of $15.3333, indicating a potential upside of 26.62%. Biogen has a consensus price target of $305.9032, indicating a potential upside of 26.54%. Given Vanda Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Vanda Pharmaceuticals is more favorable than Biogen.

Institutional and Insider Ownership

78.9% of Biogen shares are owned by institutional investors. 5.9% of Vanda Pharmaceuticals shares are owned by insiders. Comparatively, 0.5% of Biogen shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Biogen beats Vanda Pharmaceuticals on 9 of the 14 factors compared between the two stocks.

Vanda Pharmaceuticals (NASDAQ:VNDA) and Seagen (NASDAQ:SGEN) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, risk, analyst recommendations, dividends, earnings, profitability and institutional ownership.

Analyst Ratings

This is a summary of current ratings and target prices for Vanda Pharmaceuticals and Seagen, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Vanda Pharmaceuticals12402.43
Seagen161112.63

Vanda Pharmaceuticals currently has a consensus price target of $15.3333, indicating a potential upside of 26.62%. Seagen has a consensus price target of $176.75, indicating a potential upside of 6.83%. Given Vanda Pharmaceuticals' higher probable upside, analysts plainly believe Vanda Pharmaceuticals is more favorable than Seagen.

Risk & Volatility

Vanda Pharmaceuticals has a beta of 0.48, suggesting that its stock price is 52% less volatile than the S&P 500. Comparatively, Seagen has a beta of 1.13, suggesting that its stock price is 13% more volatile than the S&P 500.

Insider & Institutional Ownership

92.0% of Seagen shares are held by institutional investors. 5.9% of Vanda Pharmaceuticals shares are held by insiders. Comparatively, 31.1% of Seagen shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares Vanda Pharmaceuticals and Seagen's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Vanda Pharmaceuticals47.31%27.43%23.31%
Seagen-25.17%-18.32%-15.49%

Earnings & Valuation

This table compares Vanda Pharmaceuticals and Seagen's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Vanda Pharmaceuticals$227.19 million2.92$115.55 million$2.115.74
Seagen$916.71 million32.54$-158,650,000.00($1.33)-124.40

Vanda Pharmaceuticals has higher earnings, but lower revenue than Seagen. Seagen is trading at a lower price-to-earnings ratio than Vanda Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Summary

Seagen beats Vanda Pharmaceuticals on 8 of the 15 factors compared between the two stocks.


Vanda Pharmaceuticals Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Amgen logo
AMGN
Amgen
2.5$220.31-0.1%$128.26 billion$23.36 billion17.77Analyst Revision
Gilead Sciences logo
GILD
Gilead Sciences
2.9$59.50-1.3%$74.58 billion$22.45 billion61.34Analyst Revision
Vertex Pharmaceuticals logo
VRTX
Vertex Pharmaceuticals
2.4$218.10-0.7%$56.71 billion$4.16 billion27.54
Regeneron Pharmaceuticals logo
REGN
Regeneron Pharmaceuticals
2.1$508.31-0.4%$54.24 billion$7.86 billion19.68
Biogen logo
BIIB
Biogen
2.0$241.75-0.3%$37.20 billion$14.38 billion8.00Analyst Revision
Seagen logo
SGEN
Seagen
1.4$165.45-0.5%$29.83 billion$916.71 million-109.57Insider Selling
Alexion Pharmaceuticals logo
ALXN
Alexion Pharmaceuticals
2.1$122.93-0.1%$26.90 billion$4.99 billion28.72
Incyte logo
INCY
Incyte
1.7$81.16-0.5%$17.77 billion$2.16 billion-51.69
Exact Sciences logo
EXAS
Exact Sciences
1.6$115.87-1.2%$17.43 billion$876.29 million-52.43
Alnylam Pharmaceuticals logo
ALNY
Alnylam Pharmaceuticals
1.8$125.45-0.2%$14.57 billion$219.75 million-16.02Analyst Report
Analyst Revision
Heavy News Reporting
BioMarin Pharmaceutical logo
BMRN
BioMarin Pharmaceutical
2.0$78.15-0.2%$14.19 billion$1.70 billion17.88
Repligen logo
RGEN
Repligen
1.4$181.43-1.3%$9.55 billion$270.24 million312.82Insider Selling
Neurocrine Biosciences logo
NBIX
Neurocrine Biosciences
2.3$95.12-0.7%$8.89 billion$788.10 million45.08Analyst Downgrade
Ionis Pharmaceuticals logo
IONS
Ionis Pharmaceuticals
1.8$50.24-0.4%$7.02 billion$1.12 billion104.67Insider Selling
Unusual Options Activity
Novavax logo
NVAX
Novavax
1.8$102.60-7.1%$6.53 billion$18.66 million-37.31
United Therapeutics logo
UTHR
United Therapeutics
1.4$135.07-0.3%$6.00 billion$1.45 billion13.87
Amicus Therapeutics logo
FOLD
Amicus Therapeutics
1.2$22.76-1.0%$5.93 billion$182.24 million-19.79
Exelixis logo
EXEL
Exelixis
1.9$18.73-1.7%$5.81 billion$967.78 million39.02Insider Selling
Halozyme Therapeutics logo
HALO
Halozyme Therapeutics
1.5$41.14-1.1%$5.56 billion$195.99 million257.13Analyst Report
Insider Selling
Analyst Revision
Emergent BioSolutions logo
EBS
Emergent BioSolutions
1.8$80.41-1.5%$4.26 billion$1.11 billion25.86
Arena Pharmaceuticals logo
ARNA
Arena Pharmaceuticals
1.7$65.50-0.2%$3.81 billion$806.43 million-9.28
ChemoCentryx logo
CCXI
ChemoCentryx
1.6$54.00-3.6%$3.74 billion$36.13 million-80.60
Alkermes logo
ALKS
Alkermes
1.3$18.43-0.3%$2.93 billion$1.17 billion-40.06
OPKO Health logo
OPK
OPKO Health
1.9$3.95-1.0%$2.65 billion$901.90 million-11.97
Ironwood Pharmaceuticals logo
IRWD
Ironwood Pharmaceuticals
1.3$11.63-1.1%$1.86 billion$428.41 million16.86
Madrigal Pharmaceuticals logo
MDGL
Madrigal Pharmaceuticals
1.9$111.94-1.2%$1.73 billionN/A-10.11Analyst Report
Ligand Pharmaceuticals logo
LGND
Ligand Pharmaceuticals
1.6$87.41-1.0%$1.41 billion$120.28 million-88.29
Sangamo Therapeutics logo
SGMO
Sangamo Therapeutics
1.5$9.77-2.0%$1.38 billion$102.43 million-11.77
Myriad Genetics logo
MYGN
Myriad Genetics
1.3$18.21-2.5%$1.37 billion$638.60 million-6.79
Intercept Pharmaceuticals logo
ICPT
Intercept Pharmaceuticals
1.9$37.39-2.6%$1.23 billion$252 million-3.61Analyst Revision
Innoviva logo
INVA
Innoviva
1.1$10.56-2.2%$1.07 billion$261.02 million5.39
Codexis logo
CDXS
Codexis
1.1$17.86-0.2%$1.06 billion$68.46 million-51.03
ImmunoGen logo
IMGN
ImmunoGen
1.7$5.30-0.8%$993.90 million$82.27 million-12.33
Celldex Therapeutics logo
CLDX
Celldex Therapeutics
1.4$21.75-2.3%$860.58 million$3.57 million-9.75
BioCryst Pharmaceuticals logo
BCRX
BioCryst Pharmaceuticals
1.6$4.76-2.1%$840.45 million$48.83 million-6.26Analyst Report
MannKind logo
MNKD
MannKind
0.9$2.95-3.7%$686.17 million$63.04 million-14.05
Agenus logo
AGEN
Agenus
1.6$3.51-4.0%$667.42 million$150.05 million-3.22
Spectrum Pharmaceuticals logo
SPPI
Spectrum Pharmaceuticals
1.5$4.56-1.8%$665.40 million$109.33 million-3.74
BioSpecifics Technologies logo
BSTC
BioSpecifics Technologies
1.3$88.44-0.0%$649.59 million$38.19 million37.47
ZIOPHARM Oncology logo
ZIOP
ZIOPHARM Oncology
1.3$2.92-1.0%$625.73 million$150,000.00-4.17
Geron logo
GERN
Geron
1.4$1.81-0.0%$561.95 million$460,000.00-5.17
Rigel Pharmaceuticals logo
RIGL
Rigel Pharmaceuticals
1.6$2.93-0.3%$495.11 million$59.29 million-20.93
AMAG Pharmaceuticals logo
AMAG
AMAG Pharmaceuticals
0.8$13.75-0.0%$477.47 million$327.75 million-1.89
Dynavax Technologies logo
DVAX
Dynavax Technologies
1.7$4.25-2.4%$468.24 million$35.22 million-3.10
Molecular Templates logo
MTEM
Molecular Templates
1.6$8.84-0.6%$441.68 million$22.27 million-4.33
Clovis Oncology logo
CLVS
Clovis Oncology
1.4$4.44-1.1%$392.14 million$143.01 million-0.85
XOMA logo
XOMA
XOMA
1.4$32.66-0.5%$359.98 million$18.37 million-29.42Analyst Report
Insider Selling
PDL BioPharma logo
PDLI
PDL BioPharma
1.3$2.56-2.3%$292.42 million$54.76 million-1.92
Verastem logo
VSTM
Verastem
1.5$1.70-7.1%$288.62 million$17.46 million-1.21
Fortress Biotech logo
FBIO
Fortress Biotech
1.7$2.61-3.4%$244.57 million$36.63 million-3.00
This page was last updated on 11/26/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.